Apr 20, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks in the News: Baxalta Inc (NYSE:BXLT), Cytori Therapeutics Inc (NASDAQ:CYTX), Novavax Inc (NASDAQ:NVAX)

Stocks in the News: Baxalta Inc (NYSE:BXLT), Cytori Therapeutics Inc (NASDAQ:CYTX), Novavax Inc (NASDAQ:NVAX)

Baxalta Inc (NYSE:BXLT) stock is at $41.26, down -0.19 percent from its previous close of $41.34. The stock opened the session at $41.29 and touched its highest price point at $41.74. The company’s stock’s lowest price point for the session stood at $41.05. Its yesterday’s volume was 7.31 million shares in comparison to its usual trading volume of 11.57 million shares.

Baxalta Inc (NYSE:BXLT) on April 4, 2016 announced that the Ministry of Health, Labour and Welfare in Japan approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment, for patients 12 years and older with hemophilia A.

ADYNOVATE is built on ADVATE [Antihemophilic Factor (Recombinant)], the world’s most widely used FVIII treatment for hemophilia A with more than 12 years of patient experience. ADYNOVATE leverages proprietary pegylation technology2 designed to extend the time FVIII is available in the body. The technology reduces the speed at which ADYNOVATE is cleared from the blood, resulting in increased circulating half-life.

The approval was based on positive results of a Phase 3, prospective, global, multi-center, open label, non-randomized study in patients 12 to 65 years of age with hemophilia A. The study found that previously-treated patients in a twice-weekly prophylaxis arm had a 95 percent reduction in the median overall annualized bleed rate (ABR) compared to those treated on-demand [1.9 vs. 41.5, respectively]. During the study, nearly 40 percent (n=120) of prophylaxis-treated patients experienced zero bleeds.No patients developed inhibitors to the treatment; the most common adverse reactions (≥1 percent of subjects) were headache and nausea.

Cytori Therapeutics Inc (NASDAQ:CYTX) stock is at $0.301, down -4.14 percent from its previous close of $0.31. Its yesterday’s volume was 5.19 million shares in comparison to its usual trading volume of 1.77 million shares. Previous 5 days graph demonstrated a positive move of 29.02%. Its quarterly performance remained green with the percentage of 100.13, while its year to date performance showed that the stock advanced overall 58.42%.

Cytori Therapeutics Inc (NASDAQ:CYTX) on April 18, 2016 announced a number of key additions to its patent portfolio in Japan and Europe. The company now has 85 global patents issued, 12 of which are in Japan, and another 55 pending around the globe.

The Japanese Patent Office recently granted to Cytori patent No. 5,883,553 which is a foundational patent for the production of cellular and tissue therapeutics containing a combination of adipose tissue with adipose-derived regenerative cells. This patent broadly protects methods for manufacturing therapeutics including those currently being used in Cytori-supported ADRESU phase III urinary incontinence trial in Japan as well as many other indications in the urology, reconstructive and aesthetic markets. This patent protects the Cytori Cell Therapy™ and systems for these applications through at least 2022.

Cytori has also recently strengthened its position in the European market by adding several patents to its existing European portfolio of 8 patents, and by successfully opposing 2 third party European patents related to its core technology.

The European Patent Office granted Patent No. 1921133, which protects current and next generation cellular therapeutic manufacturing technology throughout Europe. The ‘133 patent claims protect Cytori’s technology across all of its clinical indications. Also granted were European Patents No. EP1778293 and EP1776126 that protect cellular therapeutics in the treatment of degenerative disc disease and stroke, respectively.

Novavax Inc (NASDAQ:NVAX) traded in the range of $5.26 and $5.54 in its previous trading session. The stock recorded the volume of 5.23 million shares so far, in comparison its average daily trading volume of 5.55 million shares. Company’s year to date performance remained declining as it lost almost -36.35%. The stock opened at $5.49 and its closing price for the day was $5.32, down -3.19 percent from its previous close.

Novavax Inc (NASDAQ:NVAX) on March 17, 2016 announced the appointment of Bob Darius, Senior Vice President, Quality Operations. He will be responsible for leading the global Quality Operations of the company, including both Quality Assurance and Quality Control, as well as serving as a member of the company’s senior management team.

Mr. Darius joins Novavax with over 25 years of experience in Quality Assurance, Quality Control and strategic manufacturing. As VP Quality Operations at GlaxoSmithKline (GSK) Biologicals, he provided oversight of the North American and German Vaccine Manufacturing Operations for over 10 years and most recently transitioned to Head Quality Advocacy Liaison. Mr. Darius also held positions of increasing responsibility at the Food and Drug Administration, Center for Biologics Evaluation and Research, where he was a Senior Reviewer and Inspector, Advisor to the Deputy Center Director, Medicine, on counter-bioterrorism products. He earned a Bachelor of Science degree in Biology from George Mason University and completed graduate work in biotechnology at Johns Hopkins University.


Comments are closed.